New studies forecast a doubling in global kidney cancer incidence by 2050, driven by modifiable risk factors. Concurrently, machine learning models are enhancing predictions of liver failure in genetic conditions like Wilson disease. These advancements underscore the critical role of data-driven approaches in managing rising cancer burdens and improving personalized prognostication.